Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients.
J Drugs Dermatol
; 23(6): e144-e148, 2024 06 01.
Article
em En
| MEDLINE
| ID: mdl-38834228
ABSTRACT
Bullous pemphigoid is often difficult to treat with the limited therapies available. Here, we describe clinical outcomes among 30 adults with bullous pemphigoid patients treated with dupilumab. We performed a multicenter, retrospective case series between March 2020 to August 2022. Patients received a loading dose of dupilumab 600 mg, followed by 300 mg maintenance dose with varying administration frequency tailored to individual patient response. All patients experienced at least some improvement in blister formation and pruritus, with 23 (76.7%) of patients demonstrating either complete clearance of blistering or marked response. Complete clearance of pruritus or marked response was noted in 25 (83.3%) of patients. Eight patients were effectively maintained solely on dupilumab. One (3.3%) patient reported an injection site reaction. Thirty patients represent a small sample, however, to our knowledge, this is the second largest group of BP treated with dupilumab. Furthermore, we provide an understandable framework for clinicians outside of academics to follow and assess treatment responses in their BP patients treated with dupilumab. Dupilumab should be considered as a therapeutic option in patients with bullous pemphigoid given its ability to induce sustained blistering and pruritus response in both typical and refractory cases while maintaining a favorable safety profile. J Drugs Dermatol. 2024;23(6)e144-e148. doi10.36849/JDD.8258e.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Prurido
/
Penfigoide Bolhoso
/
Anticorpos Monoclonais Humanizados
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article